Clinical Trial

Modulation of the Gut Microbiome With Pembrolizumab Following Chemotherapy in Resectable Pancreatic Cancer

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
A multi-institutional, single arm pilot study of antibiotics and pembrolizumab, following chemotherapy for the treatment of surgically resectable pancreatic cancer.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2022-07-13; most recent amendment 2024-10-11.
Status change: Not Yet Recruiting → Recruiting 2023-11-15
Trial Details
NCT Number NCT05462496
Lead Sponsor Icahn School of Medicine at Mount Sinai
Conditions Pancreatic Cancer
Enrollment 25 participants
Start Date 2023-03-16
Primary Completion 2027-08 (estimated)
Study Completion 2028-04 (estimated)
Updated on ClinicalTrials.gov 2024-10-15